Please provide your email address to receive an email when new articles are posted on . Once-daily linaclotide improved weekly spontaneous bowel movements from 1.16 to 3.41 during the 12-week ...
LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation. The recommended dose is 290 mcg for IBS-C patients and 145 mcg for CIC patients, with a 72 ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
The FDA approved linaclotide (Linzess) capsules to treat irritable bowel syndrome with constipation (IBS-C) in children age 7 years and older, the agency announced Wednesday. The decision makes the ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...
Surveyed HCPs identified reduction of days on TPN as a top priority –– Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence –– Additional ...
FDA approves drug for the treatment of both irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation in adults On August 30, 2012 LINZESS™ (linaclotide) [pronounced ...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – "With this license agreement, we have now preserved the majority of LINZESS patent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results